Clinical Trials Logo

Osteogenesis Imperfecta Type III clinical trials

View clinical trials related to Osteogenesis Imperfecta Type III.

Filter by:
  • None
  • Page 1

NCT ID: NCT05559801 Not yet recruiting - Clinical trials for Osteogenesis Imperfecta

Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)

Start date: September 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment related infusion reactions, and assessing linear growth rates and bone health, both of which are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta (CHOA) at Egleston and Emory Children's Center.

NCT ID: NCT03118570 Completed - Clinical trials for Osteogenesis Imperfecta Type III

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

Asteroid
Start date: September 11, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.

NCT ID: NCT01061099 Completed - Clinical trials for Osteogenesis Imperfecta Type III

Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta

STOD3
Start date: February 2010
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the safety and effectiveness of repeated Mesenchymal Stromal Cells (MSC) infusions to patients with Type II or III osteogenesis imperfecta (OI). Participants will receive MSC infusions approximately every 4 months to complete a total of 6 infusions over 20 months. Participants will be followed for 4 months post their last MSC infusion.